SAFE Pharma bags $72m and 36 other Greater China deals worth nearly $670m

Chinese contract research organisation (CRO) SAFE Pharmaceutical Technology has snapped up 500 million yuan ($71.8 million) in a Series D round led by two state-owned investors including SDIC Venture Capital and China Reform Holdings.